Dry Age Related Macular Degeneration
12
0
0
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
8.3%
1 terminated out of 12 trials
87.5%
+1.0% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (12)
Subtenon PRP Injection for Geographic Atrophy in Dry Age-Related Macular Degeneration
A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration
Study to Detect Dendritic Cell Recruitment in Human Retina
Hyperspectral Drusen Classification
Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration
A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD
The Safety and Tolerability of Sub-retinal Transplantation of SCNT-hES-RPE Cells in Patients With Advanced Dry AMD
Safety Study in Retinal Transplantation for Dry Age Related Macular Degeneration.
Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration
Transcorneal Electrical Stimulation Therapy for Retinal Disease
Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial